MRI in Rodent Models of Brain Disorders

Neurotherapeutics

Volumn 8, Issue 1, 2011, Pages 3-18

  Denic, Aleksandar ^a   Macura, Slobodan I ^a   Mishra, Prasanna ^a   Gamez, Jeffrey D ^b   Rodriguez, Moses ^b   Pirko, Istvan ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

brain disorders; mouse model; MRI; rodent model; Small animal MRI

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; MANGANESE; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE C 13; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN DISEASE; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; ELECTROCARDIOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; IMAGE PROCESSING; IN VIVO STUDY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PERFUSION WEIGHTED IMAGING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; RODENT; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY;

ANIMALS; BRAIN DISEASES; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; RODENTIA;

EID: 79955563276     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13311-010-0002-4     Document Type: Review

References (150)

1. Hansen G, Crooks LE, Davis P, et al. In vivo imaging of the rat anatomy with nuclear magnetic resonance. Radiology 1980; 136: 695-700.
2. Andjus RK, Dzakula Z, Markley JL, Macura S. Brain energetics and tolerance to anoxia in deep hypothermia. Ann N Y Acad Sci 2005; 1048: 10-35.
3. Raghunand N. Tissue pH measurement by magnetic resonance spectroscopy and imaging. Methods Mol Med 2006; 124: 347-364.
4. Robb RA. 3-D visualization in biomedical applications. Annu Rev Biomed Eng 1999; 1: 377-399.
5. Robb RA. The virtualization of medicine: a decade of pitfalls and progress. Stud Health Technol Inform 2002; 85: 1-7.
6. Turner R, Howseman A, Rees GE, Josephs O, Friston K. Functional magnetic resonance imaging of the human brain: data acquisition and analysis. Exp Brain Res 1998; 123: 5-12.
7. Ge Y, Grossman RI, Udupa JK, et al. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 2001; 220: 606-610.
8. http://rsb. info. nih. gov/nih-image/Default. html Website accessed 12/15/2010.
9. Suidan GL, Pirko I, Johnson AJ. A potential role for CD8+ T-cells as regulators of CNS vascular permeability. Neurol Res 2006; 28: 250-255.
10. Lukasik VM, Gillies RJ. Animal anaesthesia for in vivo magnetic resonance. NMR Biomed 2003; 16: 459-467.
11. Kannurpatti SS, Biswal BB. Effect of anesthesia on CBF, MAP and fMRI-BOLD signal in response to apnea. Brain Res 2004; 1011: 141-147.
12. Fricke ST, Vink R, Chiodo C, et al. Consistent and reproducible slice selection in rodent brain using a novel stereotaxic device for MRI. J Neurosci Methods 2004; 136: 99-102.
13. Bernstein MA, Huston J, 3rd, Ward HA. Imaging artifacts at 3. 0T. J Magn Reson Imaging 2006; 24: 735-746.
14. Yang QX, Williams GD, Demeure RJ, Mosher TJ, Smith MB. Removal of local field gradient artifacts in T2*-weighted images at high fields by gradient-echo slice excitation profile imaging. Magn Reson Med 1998; 39: 402-409.
15. Yang QX, Demeure RJ, Dardzinski BJ, Arnold BW, Smith MB. Multiple echo frequency-domain image contrast: improved signal-to-noise ratio and T2 (T2*) weighting. Magn Reson Med 1999; 41: 423-428.
16. Frahm J, Merboldt KD, Hanicke W. Direct FLASH MR imaging of magnetic field inhomogeneities by gradient compensation. Magn Reson Med 1988; 6: 474-480.
17. Ordidge RJ, Gorell JM, Deniau JC, Knight RA, Helpern JA. Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla. Magn Reson Med 1994; 32: 335-341.
18. Hennig J, Friedburg H. Clinical applications and methodological developments of the RARE technique. Magn Reson Imaging 1988; 6: 391-395.
19. Haacke EM. Susceptibility weighted imaging (SWI). Z Med Phys 2006; 16: 237.
20. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009; 30: 19-30.
21. Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn Reson Med 2004; 52: 612-618.
22. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1-25.
23. Lee BC, Vo KD, Kido DK, et al. MR high-resolution blood oxygenation level-dependent venography of occult (low-flow) vascular lesions. AJNR Am J Neuroradiol 1999; 20: 1239-1242.
24. Lin W, Mukherjee P, An H, et al. Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent. J Magn Reson Imaging 1999; 10: 118-123.
25. Reichenbach JR, Barth M, Haacke EM, et al. High-resolution MR venography at 3. 0 Tesla. J Comput Assist Tomogr 2000; 24: 949-957.
26. Reichenbach JR, Jonetz-Mentzel L, Fitzek C, et al. High-resolution blood oxygen-level dependent MR venography (HRBV): a new technique. Neuroradiology 2001; 43: 364-369.
27. Essig M, Reichenbach JR, Schad LR, et al. High-resolution MR venography of cerebral arteriovenous malformations. Magn Reson Imaging 1999; 17: 1417-1425.
28. Essig M, Reichenbach JR, Schad L, Debus J, Kaiser WA. [High resolution MR-venography of cerebral arteriovenous malformations]. Radiologe 2001; 41: 288-295.
29. Tong KA, Ashwal S, Holshouser BA, et al. Hemorrhagic shearing lesions in children and adolescents with posttraumatic diffuse axonal injury: improved detection and initial results. Radiology 2003; 227: 332-339.
30. Barth M, Nobauer-Huhmann IM, Reichenbach JR, et al. High-resolution three-dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumors at 3 Tesla: first clinical experience and comparison with 1. 5 Tesla. Invest Radiol 2003; 38: 409-414.
31. Hamans BC, Barth M, Leenders WP, Heerschap A. Contrast enhanced susceptibility weighted imaging (CE-SWI) of the mouse brain using ultrasmall superparamagnetic ironoxide particles (USPIO). Z Med Phys 2006; 16: 269-274.
32. Tan IL, van Schijndel RA, Pouwels PJ, et al. MR venography of multiple sclerosis. AJNR Am J Neuroradiol 2000; 21: 1039-1042.
33. Jacobs RE, Papan C, Ruffins S, Tyszka JM, Fraser SE. MRI: volumetric imaging for vital imaging and atlas construction. Nat Rev Mol Cell Biol 2003; (Suppl): SS10-16.
34. Dhenain M, Ruffins SW, Jacobs RE. Three-dimensional digital mouse atlas using high-resolution MRI. Dev Biol 2001; 232: 458-470.
35. MacKenzie-Graham A, Lee EF, Dinov ID, et al. A multimodal, multidimensional atlas of the C57BL/6J mouse brain. J Anat 2004; 204: 93-102.
36. Kovacevic N, Henderson JT, Chan E, et al. A three-dimensional MRI atlas of the mouse brain with estimates of the average and variability. Cereb Cortex 2004; 15: 639-645.
37. Jacobs RE, Ahrens ET, Dickinson ME, Laidlaw D. Towards a microMRI atlas of mouse development. Comput Med Imaging Graph 1999; 23: 15-24.
38. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002; 73: 141-147.
39. http://mouseatlas. caltech. edu Site accessed on 12/15/2010.
40. Lin YJ, Koretsky AP. Manganese ion enhances T1-weighted MRI during brain activation: an approach to direct imaging of brain function. Magn Reson Med 1997; 38: 378-388.
41. Drapeau P, Nachshen DA. Manganese fluxes and manganese-dependent neurotransmitter release in presynaptic nerve endings isolated from rat brain. J Physiol 1984; 348: 493-510.
42. Pautler RG, Mongeau R, Jacobs RE. In vivo trans-synaptic tract tracing from the murine striatum and amygdala utilizing manganese enhanced MRI (MEMRI). Magn Reson Med 2003; 50: 33-39.
43. Pautler RG, Koretsky AP. Tracing odor-induced activation in the olfactory bulbs of mice using manganese-enhanced magnetic resonance imaging. Neuroimage 2002; 16: 441-448.
44. Hu TC, Pautler RG, MacGowan GA, Koretsky AP. Manganese-enhanced MRI of mouse heart during changes in inotropy. Magn Reson Med 2001; 46: 884-890.
45. Pautler RG, Silva AC, Koretsky AP. In vivo neuronal tract tracing using manganese-enhanced magnetic resonance imaging. Magn Reson Med 1998; 40: 740-748.
46. Bilgen M, Dancause N, Al-Hafez B, He YY, Malone TM. Manganese-enhanced MRI of rat spinal cord injury. Magn Reson Imaging 2005; 23: 829-832.
47. Bilgen M. Imaging corticospinal tract connectivity in injured rat spinal cord using manganese-enhanced MRI. BMC Med Imaging 2006; 6: 15.
48. Stieltjes B, Klussmann S, Bock M, et al. Manganese-enhanced magnetic resonance imaging for in vivo assessment of damage and functional improvement following spinal cord injury in mice. Magn Reson Med 2006; 55: 1124-1131.
49. Yang J, Wu EX. Manganese-enhanced MRI detected the gray matter lesions in the late phase of mild hypoxic-ischemic injury in neonatal rat. Conf Proc IEEE Eng Med Biol Soc 2007; 2007: 51-54.
50. Bock C, Schmitz B, Kerskens CM, et al. Functional MRI of somatosensory activation in rat: effect of hypercapnic up-regulation on perfusion- and BOLD-imaging. Magn Reson Med 1998; 39: 457-461.
51. Mandeville JB, Marota JJ, Kosofsky BE, et al. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 1998; 39: 615-624.
52. Malisza KL, Stroman PW. Functional imaging of the rat cervical spinal cord. J Magn Reson Imaging 2002; 16: 553-558.
53. Malisza KL, Stroman PW, Turner A, et al. Functional MRI of the rat lumbar spinal cord involving painful stimulation and the effect of peripheral joint mobilization. J Magn Reson Imaging 2003; 18: 152-159.
54. Brinker G, Bock C, Busch E, et al. Simultaneous recording of evoked potentials and T2*-weighted MR images during somatosensory stimulation of rat. Magn Reson Med 1999; 41: 469-473.
55. Hsu EW, Hedlund LW, MacFall JR. Functional MRI of the rat somatosensory cortex: effects of hyperventilation. Magn Reson Med 1998; 40: 421-426.
56. Mandeville JB, Jenkins BG, Kosofsky BE, et al. Regional sensitivity and coupling of BOLD and CBV changes during stimulation of rat brain. Magn Reson Med 2001; 45: 443-447.
57. Wu EX, Wong KK, Andrassy M, Tang H. High-resolution in vivo CBV mapping with MRI in wild-type mice. Magn Reson Med 2003; 49: 765-770.
58. Lawrence J, Stroman PW, Malisza KL. Functional MRI of the cervical spinal cord during noxious and innocuous thermal stimulation in the alpha-chloralose- and halothane-anesthetized rat. Magn Reson Imaging 2008; 26: 1-10.
59. Majcher K, Tomanek B, Jasinski A, et al. Simultaneous functional magnetic resonance imaging in the rat spinal cord and brain. Exp Neurol 2006; 197: 458-464.
60. Pirko I, Ciric B, Gamez J, et al. A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2-weighted spinal cord MRI in a virus-induced murine model of MS. FASEB J 2004; 18: 1577-1579.
61. Pirko I, Johnson A, Ciric B, et al. In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies. FASEB J 2004; 18: 179-182.
62. Pirko I, Ciric B, Johnson AJ, et al. Magnetic resonance imaging of immune cells in inflammation of central nervous system. Croat Med J 2003; 44: 463-468.
63. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004; 17: 484-499.
64. Bulte JW, Arbab AS, Douglas T, Frank JA. Preparation of magnetically labeled cells for cell tracking by magnetic resonance imaging. Methods Enzymol 2004; 386: 275-299.
65. Bulte JW, Ben-Hur T, Miller BR, et al. MR microscopy of magnetically labeled neurospheres transplanted into the Lewis EAE rat brain. Magn Reson Med 2003; 50: 201-205.
66. Anderson SA, Shukaliak-Quandt J, Jordan EK, et al. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol 2004; 55: 654-659.
67. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990; 175: 489-493.
68. Shapiro EM, Skrtic S, Koretsky AP. Sizing it up: cellular MRI using micron-sized iron oxide particles. Magn Reson Med 2005; 53: 329-338.
69. Stark DD, Weissleder R, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 1988; 168: 297-301.
70. Weissleder R, Hahn PF, Stark DD, et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology 1988; 169: 399-403.
71. Robinson KM, Njus JM, Phillips DA, et al. MR imaging of inflammation during myelin-specific T cell-mediated autoimmune attack in the EAE mouse spinal cord. Mol Imaging Biol 2010; 12: 240-249.
72. Ladewig G, Jestaedt L, Misselwitz B, et al. Spatial diversity of blood-brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: a comparative MRI study. Exp Neurol 2009; 220: 207-211.
73. Xu S, Jordan EK, Brocke S, et al. Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: early histopathological correlation. J Neurosci Res 1998; 52: 549-558.
74. Dousset V, Ballarino L, Delalande C, et al. Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis. AJNR Am J Neuroradiol 1999; 20: 223-227.
75. Rausch M, Hiestand P, Baumann D, Cannet C, Rudin M. MRI-based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE. Magn Reson Med 2003; 50: 309-314.
76. Pirko I, Nolan TK, Holland SK, Johnson AJ. Multiple sclerosis: pathogenesis and MR imaging features of T1 hypointensities in a [corrected] murine model. Radiology 2008; 246: 790-795.
77. OudeEngberink RD, van der Pol SM, Dopp EA, de Vries HE, Blezer EL. Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology 2007; 243: 467-474.
78. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 2008; 29: 3583-3590.
79. Metz S, Bonaterra G, Rudelius M, et al. Capacity of human monocytes to phagocytose approved iron oxide MR contrast agents in vitro. Eur Radiol 2004; 14: 1851-1858.
80. McAteer MA, Sibson NR, von Zur Muhlen C, et al. In vivo magnetic resonance imaging of acute brain inflammation using microparticles of iron oxide. Nat Med 2007; 13: 1253-1258.
81. Querol M, Bogdanov A, Jr. Amplification strategies in MR imaging: activation and accumulation of sensing contrast agents (SCAs). J Magn Reson Imaging 2006; 24: 971-982.
82. Chen JW, Querol Sans M, Bogdanov A, Jr., Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology 2006; 240: 473-481.
83. Kim JH, Budde MD, Liang HF, et al. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol Dis 2006; 21: 626-632.
84. MacKenzie-Graham A, Tiwari-Woodruff SK, Sharma G, et al. Purkinje cell loss in experimental autoimmune encephalomyelitis. Neuroimage 2009; 48: 637-651.
85. Pirko I, Johnson AJ, Lohrey AK, Chen Y, Ying J. Deep gray matter T2 hypointensity correlates with disability in a murine model of MS. J Neurol Sci 2009; 282: 34-38.
86. Pirko I, Suidan GL, Rodriguez M, Johnson AJ. Acute hemorrhagic demyelination in a murine model of multiple sclerosis. J Neuroinflammation 2008; 5: 31.
87. Wu QZ, Yang Q, Cate HS, et al. MRI identification of the rostral-caudal pattern of pathology within the corpus callosum in the cuprizone mouse model. J Magn Reson Imaging 2008; 27: 446-453.
88. Zaaraoui W, Deloire M, Merle M, et al. Monitoring demyelination and remyelination by magnetization transfer imaging in the mouse brain at 94T. Magma 2008; 21: 357-362.
89. Sun SW, Liang HF, Trinkaus K, et al. Noninvasive detection of cuprizone induced axonal damage and demyelination in the mouse corpus callosum. Magn Reson Med 2006; 55: 302-308.
90. Pirko I, Gamez J, Johnson AJ, Macura SI, Rodriguez M. Dynamics of MRI lesion development in an animal model of viral-induced acute progressive CNS demyelination. NeuroImage 2004; 21: 576-582.
91. Pirko I, Johnson A, Gamez J, Macura SI, Rodriguez M. Disappearing "T1 black holes" in an animal model of multiple sclerosis. Front Biosci 2004; 9: 1222-1227.
92. Heide AC, Richards TL, Alvord EC, Jr., Peterson J, Rose LM. Diffusion imaging of experimental allergic encephalomyelitis. Magn Reson Med 1993; 29: 478-484.
93. Ahrens ET, Laidlaw DH, Readhead C, et al. MR microscopy of transgenic mice that spontaneously acquire experimental allergic encephalomyelitis. Magn Reson Med 1998; 40: 119-132.
94. Schwarcz A, Natt O, Watanabe T, et al. Localized proton MRS of cerebral metabolite profiles in different mouse strains. Magn Reson Med 2003; 49: 822-827.
95. Xu J, Sun SW, Naismith RT, et al. Assessing optic nerve pathology with diffusion MRI: from mouse to human. NMR Biomed 2008; 21: 928-940.
96. Wu Q, Butzkueven H, Gresle M, et al. MR diffusion changes correlate with ultra-structurally defined axonal degeneration in murine optic nerve. Neuroimage 2007; 37: 1138-1147.
97. Lee WT, Chang C. Magnetic resonance imaging and spectroscopy in assessing 3-nitropropionic acid-induced brain lesions: an animal model of Huntington's disease. Prog Neurobiol 2004; 72: 87-110.
98. Choi IY, Lee SP, Guilfoyle DN, Helpern JA. In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurochem Res 2003; 28: 987-1001.
99. Gilissen EP, Ghosh P, Jacobs RE, Allman JM. Topographical localization of iron in brains of the aged fat-tailed dwarf lemur (Cheirogaleus medius) and gray lesser mouse lemur (Microcebus murinus). Am J Primatol 1998; 45: 291-299.
100. McDaniel B, Sheng H, Warner DS, Hedlund LW, Benveniste H. Tracking brain volume changes in C57BL/6J and ApoE-deficient mice in a model of neurodegeneration: a 5-week longitudinal micro-MRI study. NeuroImage 2001; 14: 1244-1255.
101. Poduslo JF, Wengenack TM, Curran GL, et al. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis 2002; 11: 315-329.
102. Poduslo JF, Curran GL, Peterson JA, et al. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 2004; 43: 6064-6075.
103. Zhang J, Yarowsky P, Gordon MN, et al. Detection of amyloid plaques in mouse models of Alzheimer's disease by magnetic resonance imaging. Magn Reson Med 2004; 51: 452-457.
104. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 2004; 1012: 60-65.
105. Jack CR, Jr., Garwood M, Wengenack TM, et al. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn Reson Med 2004; 52: 1263-1271.
106. Jack CR, Jr., Marjanska M, Wengenack TM, et al. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist 2007; 13: 38-48.
107. Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L. Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 2001; 185: 19-26.
108. Pirko I, Johnson AJ, Lohrey AK, Chen Y, Ying J. Deep gray matter T2 hypointensity correlates with disability in a murine model of MS. J Neurol Sci 2009; 282: 34-38.
109. Chamberlain R, Reyes D, Curran GL, et al. Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease. Magn Reson Med 2009; 61: 1158-1164.
110. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
111. Angenstein F, Niessen HG, Goldschmidt J, et al. Age-dependent changes in MRI of motor brain stem nuclei in a mouse model of ALS. Neuroreport 2004; 15: 2271-2274.
112. Zang DW, Yang Q, Wang HX, et al. Magnetic resonance imaging reveals neuronal degeneration in the brainstem of the superoxide dismutase 1 transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 2004; 20: 1745-1751.
113. Bucher S, Braunstein KE, Niessen HG, et al. Vacuolization correlates with spin-spin relaxation time in motor brainstem nuclei and behavioural tests in the transgenic G93A-SOD1 mouse model of ALS. Eur J Neurosci 2007; 26: 1895-1901.
114. Niessen HG, Angenstein F, Sander K, et al. In vivo quantification of spinal and bulbar motor neuron degeneration in the G93A-SOD1 transgenic mouse model of ALS by T2 relaxation time and apparent diffusion coefficient. Exp Neurol 2006; 201: 293-300.
115. Wilson JM, Petrik MS, Grant SC, et al. Quantitative measurement of neurodegeneration in an ALS-PDC model using MR microscopy. Neuroimage 2004; 23: 336-343.
116. Hesselbarth D, Franke C, Hata R, Brinker G, Hoehn-Berlage M. High resolution MRI and MRS: a feasibility study for the investigation of focal cerebral ischemia in mice. NMR Biomed 1998; 11: 423-429.
117. Hoehn M, Nicolay K, Franke C, van der Sanden B. Application of magnetic resonance to animal models of cerebral ischemia. J Magn Reson Imaging 2001; 14: 491-509.
118. Hata R, Mies G, Wiessner C, et al. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab 1998; 18: 367-375.
119. Barber PA, Hoyte L, Kirk D, et al. Early T1- and T2-weighted MRI signatures of transient and permanent middle cerebral artery occlusion in a murine stroke model studied at 9. 4T. Neurosci Lett 2005; 388: 54-59.
120. Xue R, van Zijl PC, Crain BJ, Solaiyappan M, Mori S. In vivo three-dimensional reconstruction of rat brain axonal projections by diffusion tensor imaging. Magn Reson Med 1999; 42: 1123-1127.
121. Tatlisumak T, Strbian D, Abo Ramadan U, Li F. The role of diffusion- and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke: from laboratory to clinics. Curr Vasc Pharmacol 2004; 2: 343-355.
122. Pedrono E, Durukan A, Strbian D, et al. An optimized mouse model for transient ischemic attack. J Neuropathol Exp Neurol 2010; 69: 188-195.
123. Dreher W, Kuhn B, Gyngell ML, et al. Temporal and regional changes during focal ischemia in rat brain studied by proton spectroscopic imaging and quantitative diffusion NMR imaging. Magn Reson Med 1998; 39: 878-888.
124. Malisza KL, Kozlowski P, Ning G, Bascaramurty S, Tuor UI. Metabolite changes in neonatal rat brain during and after cerebral hypoxia-ischemia: a magnetic resonance spectroscopic imaging study. NMR Biomed 1999; 12: 31-38.
125. Beckmann N. High resolution magnetic resonance angiography non-invasively reveals mouse strain differences in the cerebrovascular anatomy in vivo. Magn Reson Med 2000; 44: 252-258.
126. Illanes S, Zhou W, Heiland S, Markus Z, Veltkamp R. Kinetics of hematoma expansion in murine warfarin-associated intracerebral hemorrhage. Brain Res 2010; 1320: 135-142.
127. Knight RA, Han Y, Nagaraja TN, et al. Temporal MRI assessment of intracerebral hemorrhage in rats. Stroke 2008; 39: 2596-2602.
128. Goetz P, Blamire A, Rajagopalan B, et al. Increase in apparent diffusion coefficient in normal appearing white matter following human traumatic brain injury correlates with injury severity. J Neurotrauma 2004; 21: 645-654.
129. Stoffel M, Blau C, Reinl H, et al. Identification of brain tissue necrosis by MRI: validation by histomorphometry. J Neurotrauma 2004; 21: 733-740.
130. Mac Donald CL, Dikranian K, Bayly P, Holtzman D, Brody D. Diffusion tensor imaging reliably detects experimental traumatic axonal injury and indicates approximate time of injury. J Neurosci 2007; 27: 11869-11876.
131. Mac Donald CL, Dikranian K, Song SK, et al. Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury. Exp Neurol 2007; 205: 116-131.
132. van Putten HP, Bouwhuis MG, Muizelaar JP, Lyeth BG, Berman RF. Diffusion-weighted imaging of edema following traumatic brain injury in rats: effects of secondary hypoxia. J Neurotrauma 2005; 22: 857-872.
133. Schuhmann MU, Stiller D, Skardelly M, et al. Metabolic changes in the vicinity of brain contusions: a proton magnetic resonance spectroscopy and histology study. J Neurotrauma 2003; 20: 725-743.
134. Schuhmann MU, Stiller D, Skardelly M, et al. Long-time in-vivo metabolic monitoring following experimental brain contusion using proton magnetic resonance spectroscopy. Acta Neurochir Suppl 2002; 81: 209-212.
135. Tsai EC, van Bendegem RL, Hwang SW, Tator CH. A novel method for simultaneous anterograde and retrograde labeling of spinal cord motor tracts in the same animal. J Histochem Cytochem 2001; 49: 1111-1122.
136. Raineteau O, Fouad K, Bareyre FM, Schwab ME. Reorganization of descending motor tracts in the rat spinal cord. Eur J Neurosci 2002; 16: 1761-1771.
137. Rosenzweig ES, McDonald JW. Rodent models for treatment of spinal cord injury: research trends and progress toward useful repair. Curr Opin Neurol 2004; 17: 121-131.
138. Nevo U, Hauben E, Yoles E, et al. Diffusion anisotropy MRI for quantitative assessment of recovery in injured rat spinal cord. Magn Reson Med 2001; 45: 1-9.
139. Lawrence J, Stroman PW, Bascaramurty S, Jordan LM, Malisza KL. Correlation of functional activation in the rat spinal cord with neuronal activation detected by immunohistochemistry. Neuroimage 2004; 22: 1802-1807.
140. Keen CL, Ensunsa JL, Clegg MS. Manganese metabolism in animals and humans including the toxicity of manganese. Met Ions Biol Syst 2000; 37: 89-121.
141. Hirakawa K, Naruse S, Higuchi T, et al. The investigation of experimental brain tumours using 31P-MRS and 1H-MRI. Acta Neurochir Suppl (Wien) 1988; 43: 140-144.
142. Gyngell ML, Els T, Hoehn-Berlage M, Hossmann KA. Proton MR spectroscopy of experimental brain tumors in vivo. Acta Neurochir Suppl (Wien) 1994; 60: 350-352.
143. Phuong LK, Allen C, Peng KW, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003; 63: 2462-2469.
144. Thu MS, Najbauer J, Kendall SE, et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS One 2009; 4: e7218.
145. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed 2001; 14: 497-506.
146. Giannini C, Sarkaria JN, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 2005; 7: 164-176.
147. Jost SC, Hope A, Kiehl E, et al. A novel murine model for localized radiation necrosis and its characterization using advanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2009; 75: 527-533.
148. Kato Y, Okollie B, Artemov D. Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn Reson Med 2006; 55: 755-761.
149. Kato Y, Holm DA, Okollie B, Artemov D. Noninvasive detection of temozolomide in brain tumor xenografts by magnetic resonance spectroscopy. Neuro Oncol 2010; 12: 71-79.
150. Pirko I, Fricke ST, Johnson AJ, Rodriguez M, Macura SI. Magnetic resonance imaging, microscopy, and spectroscopy of the central nervous system in experimental animals. NeuroRx 2005; 2: 250-264.